At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 200 target
Drug / intervention
Placebo Comparator +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating Placebo Comparator and CM512 for Atopic Dermatitis. Currently recruiting, targeting 200 participants across 1 site.
Detailed Summary
A Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
2026
First PostedApr 2025
Enrollment StartJun 2025
TodayJul 2026
Primary CompletionJul 2026
Study CompletionNov 2026
First PostedApr 27, 2025
Enrollment StartJun 19, 2025
Primary CompletionJul 18, 2026
Study CompletionNov 7, 2026
TodayJul 1, 2026
Enrollment to primary: 1.1 yearsPosted 1.2 years agoPrimary completion in 17 days
Interventions
Placebo Comparatordrug
Placebo subcutaneous injection
CM512biological
CM512 subcutaneous injection